Mitsubishi Tanabe Pharma is offering Dewpoint Therapeutics up to $480 million biobucks in a new research pact centering ...
The results of CardinALS showed utreloxastat failed to meet its main and secondary goals, including several disease-related ...
The Phase 1 trial ANQUR, now testing two new doses of the ALS therapy QRL-201, is enrolling patients at 12 sites in Canada ...
Novartis is paying $1 billion upfront for global rights to PTC Therapeutics’ midphase Huntington's disease program, helping ...
Monday’s agreement comes days after PTC discontinued the development of another asset, utreloxastat, due to disappointing ...
Scientists have uncovered a link between ancient viral elements embedded in human DNA and the genetic risk for two major ...
Both companies will collaborate to advance a small molecule condensate modulator targeting TDP-43, with the potential to address the underlying ...
Bulbar onset ALS is a type of amyotrophic lateral sclerosis (ALS) that affects the muscles in the face, neck, and throat. Symptoms include slurred speech, difficulty swallowing, weakness in the ...
The global amyotrophic lateral sclerosis treatment market size was US$ 637.2 million in 2021. The global amyotrophic lateral sclerosis treatment market is forecast to grow to US$ 918 million by 2030, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback